Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

GSK2982772 is a highly selective inhibitor of receptor‐interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases. This first‐in‐human study evaluated safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of GSK2982772 administered orally...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Kathleen, Scott, Nicola E., Tompson, Debra J., Votta, Bartholomew J., Madhavan, Sujith, Povey, Kat, Wolstenholme, Allen, Simeoni, Monica, Rudo, Todd, Richards‐Peterson, Lauren, Sahota, Tarjinder, Wang, J. Gene, Lich, John, Finger, Joshua, Verticelli, Adeline, Reilly, Michael, Gough, Peter J., Harris, Philip A., Bertin, John, Wang, Mei‐Lun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723699/
https://www.ncbi.nlm.nih.gov/pubmed/29226626
http://dx.doi.org/10.1002/prp2.365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723699/
https://www.ncbi.nlm.nih.gov/pubmed/29226626
http://dx.doi.org/10.1002/prp2.365

Ejemplares similares